Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group
(2017) In Dermatitis 28(3). p.215-218- Abstract
Background: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. Objectives: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Patients and Methods: Two thousand seven hundred three consecutive patients with dermatitis... (More)
Background: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. Objectives: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Patients and Methods: Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. Results: Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P G 0.001). Conclusions: Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 Kg/cm2) diagnoses significantly more contact allergy than 0.01% (dose, 3 Kg/cm2), without resulting in more adverse reactions.Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.
(Less)
- author
- Engfeldt, Malin LU ; Ale, Iris ; Andersen, Klaus E. ; Elsner, Peter ; Goh, Chee Leok ; Goossens, An ; Jerajani, Hemangi ; Matsunaga, Kayoko and Bruze, Magnus LU
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Dermatitis
- volume
- 28
- issue
- 3
- pages
- 4 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- scopus:85021076977
- wos:000401707100006
- pmid:28509716
- ISSN
- 1710-3568
- DOI
- 10.1097/DER.0000000000000287
- language
- English
- LU publication?
- yes
- id
- fab73a38-5d1d-44cc-94a5-16fb365489e9
- date added to LUP
- 2017-07-28 13:53:03
- date last changed
- 2024-05-12 18:08:07
@article{fab73a38-5d1d-44cc-94a5-16fb365489e9,
abstract = {{<p>Background: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. Objectives: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Patients and Methods: Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. Results: Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P G 0.001). Conclusions: Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 Kg/cm2) diagnoses significantly more contact allergy than 0.01% (dose, 3 Kg/cm2), without resulting in more adverse reactions.Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.</p>}},
author = {{Engfeldt, Malin and Ale, Iris and Andersen, Klaus E. and Elsner, Peter and Goh, Chee Leok and Goossens, An and Jerajani, Hemangi and Matsunaga, Kayoko and Bruze, Magnus}},
issn = {{1710-3568}},
language = {{eng}},
number = {{3}},
pages = {{215--218}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Dermatitis}},
title = {{Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group}},
url = {{http://dx.doi.org/10.1097/DER.0000000000000287}},
doi = {{10.1097/DER.0000000000000287}},
volume = {{28}},
year = {{2017}},
}